Cox John 4
4 · Dyne Therapeutics, Inc. · Filed Sep 4, 2024
Insider Transaction Report
Form 4
Cox John
DirectorCEO & President
Transactions
- Purchase
Common Stock
2024-09-04$32.57/sh+800$26,056→ 800 total(indirect: By Trust) - Purchase
Common Stock
2024-09-04$33.09/sh+7,200$238,248→ 8,000 total(indirect: By Trust) - Purchase
Common Stock
2024-09-04$32.57/sh+800$26,056→ 800 total(indirect: By Trust) - Purchase
Common Stock
2024-09-04$33.09/sh+7,200$238,248→ 8,000 total(indirect: By Trust) - Purchase
Common Stock
2024-09-04$32.57/sh+800$26,056→ 800 total(indirect: By Trust) - Purchase
Common Stock
2024-09-04$32.57/sh+800$26,056→ 800 total(indirect: By Trust) - Purchase
Common Stock
2024-09-04$33.09/sh+7,200$238,248→ 8,000 total(indirect: By Trust) - Purchase
Common Stock
2024-09-04$33.09/sh+7,200$238,248→ 8,000 total(indirect: By Trust)
Holdings
- 5,000
Common Stock
Footnotes (3)
- [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices within the range of $32.55 to $32.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4.
- [F2]These shares are held in a trust for the benefit of a child of the Reporting Person.
- [F3]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices within the range of $32.60 to $33.58, inclusive.